Lundbeck

LATEST NEWS: Lundbeck

Key update (19 April 2026)

Lundbeck announced new clinical findings at the American Academy of Neurology (AAN) 2026 meeting, focusing on its migraine treatment Vyepti (eptinezumab).

New real-world data from the INFUSE study showed improvements in cognitive symptoms linked to migraine (often described as “brain fog”).

More than 50% of patients reported improvements in cognitive issues such as concentration, decision-making, and mental clarity after treatment.

The study highlights a shift toward treating the broader burden of migraine, not just headache frequency.

👉 This is significant because cognitive symptoms have historically been understudied in migraine care.

🔬 Context from earlier April updates

On 13 April, Lundbeck outlined a broader pipeline push, including:

New migraine therapies (including experimental antibody treatments)

Rare epilepsy research

Neurodegenerative disease work

🧭 What it means

Lundbeck is doubling down on brain health and neurology innovation

Strong focus on real-world patient outcomes, not just clinical endpoints

Continued investment in migraine as a major growth area